tbuckley/cabot-search huggingface dataset:
Heart Transplantation Is Associated with an Increased Risk for Pancreaticobiliary Disease
Authors: Kenneth J. Vega, Ileana Piña, Benjamin Krevsky
Journal: Annals of Internal Medicine (1996)

To determine the risk factors for and the incidence, morbidity, mortality, and outcome of pancreaticobiliary disease in patients who have had orthotopic heart transplantation.Retrospective case-control analysis.University hospital-based heart transplantation center.20 case-patients with pancreaticobiliary disease and 40 controls; all patients received heart transplants between 1985 and 1994. Controls were matched to case-patients by time of transplantation and length of survival.Charts were reviewed and data were extracted using a structured data abstraction protocol. Risk factors assessed before transplantation were cause of heart disease, history of diabetes, reproductive history, and sex. Risk factors assessed at presentation of pancreaticobiliary disease were weight change after transplantation, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent rejection episode, cyclosporine level, complete blood count, time between transplantation and onset of symptoms, body mass index, calcium level, liver function test results before and at symptom onset, and lipid profile.Pancreaticobiliary disease occurred in 20 of 255 transplant recipients (7.8%). The incidence of disease in these patients within 1 year after transplantation was 3.9% compared with an expected rate of 0.2% per year (P < 0.01). A decreased serum calcium level was the only risk factor found to differ significantly between the two groups (mean +/- SD, 2.19 +/- 0.17 mmol/L in case-patients and 2.31 +/- 0.14 mmol/L in controls; P = 0.005). The duration of hospitalization for the treatment of pancreaticobiliary disease was longer for patients who received transplants than for patients who did not receive transplants and were treated at Temple University Hospital during a similar period (17.1 days compared with 7.2 days; P < 0.001). However, the outcome was excellent in most patients.Pancreaticobiliary disease occurs 17.4 times (95% CI, 9.2 to 32.7 times) more frequently in patients receiving transplants than in the general population. It is a seldom recognized but apparently common complication of orthotopic heart transplantation that results in substantial morbidity and health care resource use. Further study is needed to ascertain why this condition occurs and how the risk for developing it can be reduced.
AIDS will affect us all eventually, Mandela tells London audience
Authors: D. Carlisle
Journal: BMJ (2003)

Nelson Mandela has called for a new war against HIV/AIDS, arguing that it is claiming more lives in Africa than the sum total of all wars, famines, floods, and other deadly diseases, such as malaria.

Speaking in London at the British Red Cross 2003 humanity lecture, the former South African president described HIV/AIDS as a “new war of global dimensions.” He said: “AIDS represents a tragedy of unprecedented proportions, unfolding particularly in Africa but with incidence …
Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera
Authors: A. Baldo, E. Sammarco, R. Plaitano, V. Martinelli, G. Monfrecola
Journal: British Journal of Dermatology (2002)

Journal Article Narrowband (TL‐01) ultraviolet B phototherapy for pruritus in polycythaemia vera Get access A. Baldo, A. Baldo Departments of Dermatology and Search for other works by this author on: Oxford Academic Google Scholar E. Sammarco, E. Sammarco Departments of Dermatology and Search for other works by this author on: Oxford Academic Google Scholar R. Plaitano, R. Plaitano Departments of Dermatology and Search for other works by this author on: Oxford Academic Google Scholar V. Martinelli, V. Martinelli Haematology, University of Naples ′Federico II', Via Pansini 5, 80131 Naples, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Monfrecola G. Monfrecola Departments of Dermatology and Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 147, Issue 5, 1 November 2002, Pages 979–981, https://doi.org/10.1046/j.1365-2133.2002.04983.x Published: 01 November 2002 Article history Accepted: 02 May 2002 Published: 01 November 2002
Association between the IL-1 family gene cluster and spondyloarthritis
Authors: Dominique Monnet, Amir Kadi, Brigitte Izac, Nicolas Lebrun, Franck Letourneur, Elena Zinovieva, Roula Said-Nahal, Gilles Chiocchia, Maxime Breban
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Objective</h3> Spondyloarthritis is a group of articular disorders sharing a genetic background. Polymorphisms in the IL-1 gene cluster have previously been associated with ankylosing spondylitis (AS), a subset of spondyloarthritis. This study examined the association between several of these polymorphisms and the whole spondyloarthritis. Particular attention was devoted to genotype–phenotype correlations. <h3>Methods</h3> Seven single-nucleotide polymorphisms (SNP) and a variable number tandem repeat located in the IL-1 gene cluster were genotyped in 185 independent spondyloarthritis trios. Family-based association test (FBAT) was computed using the FBAT software. Analysis was carried in spondyloarthritis as a whole and also in AS. A case–control replication study was performed for four of the SNP, in an independent sample of 414 spondyloarthritis and 264 controls. A combined analysis of both studies was performed. <h3>Results</h3> The SNP rs2856836 in IL1A was significantly associated with spondyloarthritis (p=0.009) and AS (p=0.010) in the family study. The case–control study revealed an association between another IL1A variant (rs1894399) and AS (p=0.035), and between IL1F10.3 (rs3811058) and spondyloarthritis (p=0.041). By combining family and case–control studies an association between AS and IL1A was confirmed (rs1894399, p=0.024), whereas non-AS was more significantly associated with IL1F10.3 (p=0.0043). Family-based and case–control studies revealed significant association between the two most frequent haplotypes combining the four SNP of the replication study and both spondyloarthritis (p=0.0054 and p=0.038) and AS phenotypes (p=0.018 and 0.0036). <h3>Conclusion</h3> This study is the first to demonstrate an association between several polymorphisms located in the IL-1 gene cluster and spondyloarthritis as a whole. The IL1A locus was strongly associated with AS phenotype, whereas IL1F10 was associated with non-AS.
Effects of A3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart
Authors: Glenn Harrison, Rachael J Cerniway, Jason Nigel John Peart, Stuart S Berr, Kevin John Ashton, Sara Regan, G Paul Matherne, John Patrick Headrick
Journal: Cardiovascular Research (2002)

To characterize effects of A(3) adenosine receptor (A(3)AR) activation and gene knock-out on responses to ischemia-reperfusion in mouse heart.Perfused hearts from wild-type and A(3)AR gene knock-out (A(3)AR KO) mice were subjected to 20 min ischemia and 30 min reperfusion. Functional responses were assessed and changes in energy metabolism and cytosolic pH monitored via 31P-NMR spectroscopy.Selective A(3)AR agonism with 100 nM 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (chloro-IB-MECA) enhanced post-ischemic contractile recovery without altering contracture development in wild-type hearts, an effect unrelated to non-selective activation of A(1) or A(2) adenosine receptors. Chloro-IB-MECA also improved recovery in hearts overexpressing A(1)ARs. Paradoxically, post-ischemic recovery was enhanced by A(3)AR KO. Developed pressure, +dP/dt, and -dP/dt all recovered to higher levels in A(3)AR KO (70-80% of pre-ischemia) vs. wild-type hearts (45-50% of pre-ischemia) (P<0.05). Enhanced recovery was unrelated to recoveries of ATP, phosphocreatine (PCr), inorganic phosphate (P(i)), energy state ([ATP]/[ADP] x [P(i)], DeltaG(ATP)) or cytosolic pH.Selective A(3)AR activation is cardioprotective in wild-type hearts and hearts overexpressing A(1)ARs, yet A(3)AR gene deletion generates an ischemia-tolerant phenotype without altering energy metabolism or pH. This may be due to compensatory changes or undefined genotypic differences in A(3)AR KO vs. wild-type hearts.
A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction☆
Authors: J GAVIRA, M PEREZILZARBE, G ABIZANDA, A GARCIARODRIGUEZ, J ORBE, J PARAMO, M BELZUNCE, G RABAGO, J BARBA, J HERREROS
Journal: Cardiovascular Research (2006)

Objective: Our aim was to compare the efficacy of surgical versus percutaneous administration of skeletal myoblasts (SkM) in a swine model of chronic myocardial infarction and to determine the mechanism(s) involved in their beneficial effect.
Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
Authors: Sean P. Dineen, Kristi D. Lynn, Shane E. Holloway, Andrew F. Miller, James P. Sullivan, David S. Shames, Adam W. Beck, Carlton C. Barnett, Jason B. Fleming, Rolf A. Brekken
Journal: Cancer Research (2008)

Abstract Macrophages are an abundant inflammatory cell type in the tumor microenvironment that can contribute to tumor growth and metastasis. Macrophage recruitment into tumors is mediated by multiple cytokines, including vascular endothelial growth factor (VEGF), which is thought to function primarily through VEGF receptor (VEGFR) 1 expressed on macrophages. Macrophage infiltration is affected by VEGF inhibition. We show that selective inhibition of VEGFR2 reduced macrophage infiltration into orthotopic pancreatic tumors. Our studies show that tumor-associated macrophages express VEGFR2. Furthermore, peritoneal macrophages from tumor-bearing animals express VEGFR2, whereas peritoneal macrophages from non–tumor-bearing animals do not. To our knowledge, this is the first time that tumor-associated macrophages have been shown to express VEGFR2. Additionally, we found that the cytokine pleiotrophin is sufficient to induce VEGFR2 expression on macrophages. Pleiotrophin has previously been shown to induce expression of endothelial cell markers on macrophages and was present in the microenvironment of orthotopic pancreatic tumors. Finally, we show that VEGFR2, when expressed by macrophages, is essential for VEGF-stimulated migration of tumor-associated macrophages. In summary, tumor-associated macrophages express VEGFR2, and selective inhibition of VEGFR2 reduces recruitment of macrophages into orthotopic pancreatic tumors. Our results show an underappreciated mechanism of action that may directly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway. [Cancer Res 2008;68(11):4340–6]
Reliability and validity of measures taken during the Chester step test to predict aerobic power and to prescribe aerobic exercise
Authors: J P Buckley, J Sim, R G Eston, R Hession, R Fox
Journal: British Journal of Sports Medicine (2004)

Objectives: To evaluate the reliability and validity of measures taken during the Chester step test (CST) used to predict VO 2 max and prescribe subsequent exercise. Methods: The CST was performed twice on separate days by 7 males and 6 females aged 22.4 (SD 4.6) years. Heart rate (HR), ratings of perceived exertion (RPE), and oxygen uptake (VO 2 ) were measured at each stage of the CST. Results: RPE, HR, and actual VO 2 were the same at each stage for both trials but each of these measures was significantly different between CST stages (p&lt;0.0005). Intertrial bias ±95% limits of agreement (95% LoA) of HR reached acceptable limits at CST stage IV (−2±10 beats/min) and for RPE at stages III (0.2±1.4) and IV (0.5±1.9). Age estimated HRmax significantly overestimated actual HRmax of 5 beats/min (p = 0.016) and the 95% LoA showed that this error could range from an underestimation of 17 beats/min to an overestimation of 7 beats/min. Estimated versus actual VO 2 at each CST stage during both trials showed errors ranging between 11% and 19%. Trial 1 underestimated actual VO 2 max by 2.8 ml/kg/min (p = 0.006) and trial 2 by 1.6 ml/kg/min (not significant). The intertrial agreement in predicted VO 2 max was relatively narrow with a bias ±95% LoA of −0.8±3.7 ml/kg/min. The RPE and %HRmax (actual) correlation improved with a second trial. At all CST stages in trial 2 RPE:%HRmax coefficients were significant with the highest correlations at CST stages III ( r = 0.78) and IV ( r = 0.84). Conclusion: CST VO 2 max prediction validity is questioned but the CST is reliable on a test-retest basis. VO 2 max prediction error is due more to VO 2 estimation error at each CST stage compared with error in age estimated HRmax. The HR/RPE relation at &gt;50% VO 2 max reliably represents the recommended intensity for developing cardiorespiratory fitness, but only when a practice trial of the CST is first performed.
Misunderstanding Regarding the Carboplatin Dose Comparison in MRC TE19/EORTC 30982
Authors: Jay Lipshitz
Journal: Journal of Clinical Oncology (2011)

TO THE EDITOR: In the thoughtful editorial by Bosl and Patel, there appeared to be a misunderstanding of the exploratory analysis of the effect of carboplatin dose on outcome in stage I seminoma presented by Oliver et al in the same issue of Journal of Clinical Oncology. The editorial states that “because the prescribed dose was AUC 7, numerous protocol violations must have occurred, probably because the treating physicians were concerned by the effects of thrombocytopenia.” In fact, the exploratory analysis was not between patients who received the prescribed dose and those who received a lower dose because of protocol violation. Rather the TE19 protocol allowed for two methods of calculating glomerular filtration rate (GFR), EDTA (or a comparable isotope) technique and 24-hour urinary creatinine clearance. Those patients who had GFR calculated by the EDTA technique were given the full carboplatin dose of AUC 7. Those in whom GFR was calculated by 24-hour urine creatinine clearance were given only 90% of the AUC 7 dose. Oliver et al state that the exploratory analysis regarding the impact of carboplatin dose was made between these two groups. Because the authors felt that GFR was determined by both methods with comparable accuracy, one group received 10% less carboplatin than the other and a comparison of the two cohorts was performed. In their discussion, Oliver et al address the possible confounders of such an analysis, but the analysis does not in any way suggest that there were “numerous protocol violations” in their study.
Racial Disparities in Breast Cancer
Authors: Colleen D. Murphy, Richard D. Schulick
Journal: JAMA Surgery (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Proliferative kinetics in cultured dermal papilla cells from human hair follicles
Authors: K. Katsuoka, O.P. Hornstein, H. Schell, E. Deinlein
Journal: British Journal of Dermatology (1985)

Journal Article Proliferative kinetics in cultured dermal papilla cells from human hair follicles Get access K. Katsuoka, K. Katsuoka Department of Dermatology, University of Erlangen, Hartmannstraβe 14, D‐8520 Erlangen, W. Germany Search for other works by this author on: Oxford Academic Google Scholar O.P. Hornstein, O.P. Hornstein Department of Dermatology, University of Erlangen, Hartmannstraβe 14, D‐8520 Erlangen, W. Germany Search for other works by this author on: Oxford Academic Google Scholar H. Schell, H. Schell Department of Dermatology, University of Erlangen, Hartmannstraβe 14, D‐8520 Erlangen, W. Germany Search for other works by this author on: Oxford Academic Google Scholar E. Deinlein E. Deinlein Department of Dermatology, University of Erlangen, Hartmannstraβe 14, D‐8520 Erlangen, W. Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 113, Issue 5, 1 November 1985, Page 629, https://doi.org/10.1111/j.1365-2133.1985.tb02390.x Published: 01 November 1985
Pharmacology of the Autonomic System
Authors: G. M. Lees
Journal: BMJ (1970)

stated.Methods of administration are de- scribed, the relation of toxicity to carcin- oma regression evaluated, and factors influencing response reviewed.Regarding results, a slightly more favourabie result overall is shown for the 5-FU group as compared with the survival of the selecred control patients.Observations on other drugs used include the comments that mitomycin C produces regression comparable with the fluorinated pyrimidines but is of limited usefulness owing to toxic and other effects, and though B.C.N.U. is therapeutically ac- tive it has no practical role in treatment.Regional perfusion or infusion it seems has no advantage to offer over systemic chemo- therapy, but combined 5-FU and super- voltage radiotherapy produced a significant prolongation of life in adenocarcinoma of the stomach and pancreas.This book is helpful in looking at a very bleak problem, for it shows what can be done for these patients and eliminates for us some measures which might prove harmful.And it does demonstrate the fact that we can consider the treatment of intractable solid cancers with chemicals.
Abstract 3289: Tissue specific expression of the PI 3-kinase mutation Pik3caH1047R induces hyperplasia and tumorigenesis in a mouse model
Authors: Kathryn M. Kinross, Anjali Tikoo, Lauren Hare, Karen G. Montgomery, Wayne A. Phillips
Journal: Cancer Research (2012)

Abstract Mutations in the p110α subunit of phosphoinositide 3-kinase (PI3K) (encoded by the gene PIK3CA) are frequent in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis in vivo, we generated a conditional (Cre recombinase-inducible) knock-in mouse model of the common activating mutation, Pik3caH1047R, expressed from the endogenous locus. We have then targeted the mutation to specific tissues by crossing our mouse to mice expressing Cre under the control of tissue-specific promoters. The mouse mammary gland was targeted using a transgenic mouse expressing Cre under the control of the mouse mammary tumor virus promoter (MMTV-Cre). To target the gastrointestinal tract, we used the A33CrePR2 mouse, expressing Ru486-inducible version of Cre under the control of the gpa33 promoter. Tumors were formed in both these models but only following a long latency (&amp;gt;15 months) suggesting that a ‘second-hit’ may be necessary for tumor development. Similarly, activation of this mutation in the mouse ovary, by injection of an adenovirus expressing Cre into the ovarian bursa, revealed that Pik3caH1047R alone is a weak activator of AKT capable of inducing premalignant hyperplasia in ovarian surface epithelium. Interestingly, we found that combining Pik3caH1047R mutation with deletion of Pten in the mouse ovary resulted in robust epithelial AKT signaling and progression to ovarian serous adenocarcinomas and granulosa cell tumors within 6 months. Therapeutic inhibition of PI3K/mTOR in these mice delayed tumor growth and prolonged survival. This novel mouse is proving to be a fascinating model with which to explore the biological consequences and clinical significance of Pik3caH1047R mutation in diverse tissue types and a valuable tool for the preclinical evaluation of PI3K pathway inhibitors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3289. doi:1538-7445.AM2012-3289
Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia with and without Calcium Pretreatment
Authors: DAVID M. SALERNO
Journal: Annals of Internal Medicine (1987)

Verapamil was given to 16 consecutive patients with multifocal atrial tachycardia. Intravenous verapamil was administered at a rate of up to 1 mg/min while heart rate and systolic blood pressure were being monitored. The final 5 patients received 1 g of intravenous calcium gluconate 5 minutes before treatment with verapamil; the first 11 received no calcium. The mean heart rate decreased by 21% from 129 to 101 beats/min, a difference of 28, 95% confidence interval (Cl), 18 to 38 (p < 0.0005 by t-test), after a mean of 22 ± 13 minutes from the start of verapamil administration. The mean verapamil dose was 17 ± 7 mg (6 to 30 mg). Sinus rhythm was restored in 8 patients. Pretreatment with calcium did not block the effect of verapamil on heart rate (27% decrease with calcium compared with 19% decrease without calcium, a difference of 8%, 95% Cl, -7 to 23; p = 0.29) but minimized the decrease in systolic pressure (11% decrease with calcium compared with 27% decrease without calcium, a difference of 16%, 95% Cl, 7 to 27; p < 0.01). Verapamil caused transient asymptomatic hypotension in 1 patient. Arterial blood gases were unchanged by verapamil. Thus, verapamil is safe and effective therapy for multifocal atrial tachycardia, consistently slowing the heart rate and often restoring sinus rhythm. Calcium pretreatment may reduce drug-induced hypotension without preventing the antiarrhythmic effect.
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: identification of the target vessel by myocardial contrast echocardiography
Authors: L. Faber, H. Seggewiss, D. Fassbender, S. Strick, N. Bogunovic, U. Gleichmann
Journal: Journal of the American College of Cardiology (1998)